Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prism Biolab CoTSE:206A -1.37%11 Beneish M-Score is 0.09 as of Jul. 17, 2026. GuruFocus rates TSE:206A with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 824 Biotechnology companies, Prism Biolab Co ranks worse than 83.98% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 0.09 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Prism Biolab Co's Beneish M-Score or its related term are showing as below:
TSE:206A'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.14 Med: -1.53 Max: 0.09
Current: 0.09
During the past 4 years, the highest Beneish M-Score of Prism Biolab Co was 0.09. The lowest was -3.14. And the median was -1.53.
Prism Biolab Co Beneish M-Score Related Terms
Prism Biolab Co Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Prism Biolab Co's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:206A vs VRTX, REGN, ALNY: Beneish M-Score Comparison
For the Biotechnology subindustry, Prism Biolab Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prism Biolab Co Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prism Biolab Co's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Prism Biolab Co's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Prism Biolab Co for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1
+
0.528 * 1.3189
+
0.404 * 1.5105
+
0.892 * 2.2162
+
0.115 * 1
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1
+
4.679 * 0.205679
-
0.327 * 0.5325
=
0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0 / (0 + 0))
/
(0 / (0 + 0))
=
/
=
1
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-833.7 - 0
-
-1468.363)
/
3085.692
=
0.205679
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Prism Biolab Co has a M-score of 0.09 signals that the company is likely to be a manipulator.
Prism Biolab Co (TSE:206A) has a Beneish M-Score of 0.09 as of Jul. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Prism Biolab Co and its competitors. According to the industry distribution chart, Prism Biolab Co ranks #692 out of 824 companies in the Biotechnology industry, placing it in the top 84%.
Is Prism Biolab Co's Beneish M-Score too high?
Prism Biolab Co's current Beneish M-Score is 0.09. Based on the distribution chart, Prism Biolab Co ranks #692 out of 824 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prism Biolab Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Prism Biolab Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prism Biolab Co ranks #692 out of 824 companies for Beneish M-Score. This places Prism Biolab Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Prism Biolab Co and its competitors. Prism Biolab Co's current Beneish M-Score is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prism Biolab Co stock overvalued right now?
Prism Biolab Co (TSE:206A) has a current Beneish M-Score of 0.09. The current Beneish M-Score is 0.09. Prism Biolab Co's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Prism Biolab Co (TSE:206A), the current Beneish M-Score is 0.09 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:206A has been successfully added to your 
